After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 20% aftermarket. The company said the ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.

Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price ...

Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial testing the regimen as an adjuvant therapy for patients whose melanoma has been surgically ...

Objectives: This study aimed to identify, measure and evaluate expected costs of innovative palonosetron-based antiemetic therapy versus ondansetron-based treatment, the ultimate aim being to ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in ...